X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2665) 2665
Publication (310) 310
Book Chapter (47) 47
Book Review (34) 34
Book / eBook (4) 4
Magazine Article (3) 3
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1536) 1536
hepatitis c virus (1420) 1420
hepatitis c (1304) 1304
humans (1113) 1113
direct-acting antivirals (1069) 1069
gastroenterology & hepatology (785) 785
antiviral agents - therapeutic use (767) 767
hepatitis (653) 653
antiviral agents (650) 650
ribavirin (637) 637
hepatitis c, chronic - drug therapy (629) 629
interferon (593) 593
sofosbuvir (518) 518
hcv (461) 461
male (461) 461
female (441) 441
sustained virological response (431) 431
infectious diseases (423) 423
middle aged (420) 420
health aspects (419) 419
hepacivirus - genetics (403) 403
cirrhosis (391) 391
genotype (387) 387
therapy (375) 375
hepacivirus - drug effects (371) 371
virus-infection (361) 361
drug therapy, combination (339) 339
treatment outcome (336) 336
infection (329) 329
direct-acting antiviral (315) 315
hepatitis c - drug therapy (310) 310
liver (309) 309
virus diseases (308) 308
direct-acting antiviral agents (307) 307
infections (302) 302
direct acting antivirals (292) 292
adult (288) 288
patients (286) 286
virology (278) 278
aged (271) 271
viruses (269) 269
analysis (267) 267
liver cirrhosis (259) 259
drug therapy (257) 257
care and treatment (252) 252
sustained virologic response (251) 251
biological response modifiers (248) 248
pharmacology & pharmacy (241) 241
genotype 1 infection (240) 240
chronic hepatitis c (233) 233
hepatitis c, chronic - virology (231) 231
hepatocellular carcinoma (210) 210
antiviral agents - adverse effects (206) 206
digestive system diseases (200) 200
daclatasvir (199) 199
ribavirin - therapeutic use (199) 199
hiv (198) 198
antiviral agents - administration & dosage (194) 194
ledipasvir (189) 189
hcv infection (188) 188
pegylated interferon (186) 186
immunology (184) 184
treatment-naive patients (184) 184
genotypes (183) 183
genotype 1 (182) 182
hepatology (177) 177
hepatitis c, chronic - complications (176) 176
protease inhibitors (175) 175
hepatitis-c virus (173) 173
antiviral agents - pharmacology (170) 170
efficacy (169) 169
prevalence (169) 169
telaprevir (169) 169
liver transplantation (166) 166
plus ribavirin (165) 165
medical research (163) 163
medicine & public health (161) 161
gastroenterology and hepatology (159) 159
microbiology (158) 158
safety (158) 158
genotype & phenotype (156) 156
genetic aspects (153) 153
direct‐acting antivirals (152) 152
fibrosis (152) 152
medicine, experimental (150) 150
hepatocellular-carcinoma (149) 149
risk factors (148) 148
transplantation (137) 137
epidemiology (136) 136
liver diseases (136) 136
chronic hepatitis-c (134) 134
review (132) 132
medicine, general & internal (129) 129
treatment-naive (129) 129
antiviral therapy (128) 128
recurrence (127) 127
chronic infection (124) 124
boceprevir (122) 122
hepatitis c - virology (122) 122
mortality (122) 122
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2524) 2524
Korean (66) 66
Spanish (48) 48
Hungarian (24) 24
Japanese (23) 23
French (16) 16
German (16) 16
Russian (9) 9
Chinese (3) 3
Italian (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
Liver International, ISSN 1478-3223, 07/2017, Volume 37, Issue 7, pp. 974 - 981
Background & Aims The aim of this study was to assess the efficacy and safety of direct‐acting antivirals (DAA)‐based antiviral therapies for HCV patients with... 
direct‐acting antiviral | stage 4‐5 chronic kidney disease | hepatitis C virus infection | meta‐analysis | meta-analysis | direct-acting antiviral | stage 4-5 chronic kidney disease | ASUNAPREVIR | RENAL-DISEASE | COMBINATION | DIALYSIS PATIENTS | PEGYLATED INTERFERON | GENOTYPE 1 INFECTION | HEMODIALYSIS | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Male | Renal Insufficiency, Chronic - complications | Time Factors | Adult | Female | Hepatitis C - complications | Renal Insufficiency, Chronic - diagnosis | Drug Therapy, Combination | Odds Ratio | Kidney - physiopathology | Hepacivirus - drug effects | Severity of Illness Index | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Renal Insufficiency, Chronic - physiopathology | Hepatitis C - diagnosis | Antiviral Agents - adverse effects | Hepatitis C - virology | Hepacivirus - growth & development | Aged | Sustained Virologic Response | Antiviral agents | Care and treatment | Chronic kidney failure | Hepatitis C virus | Health aspects | Analysis | Renal function | Ritonavir | Viruses | Disease control | Patients | Incidence | Confidence intervals | Hepatitis | Renal failure | Dialysis | Libraries | Kidney diseases | Safety | Hepatitis C | Kidney transplantation
Journal Article
Journal Article
Journal Article